Ersin Akinci

Ersin Akinci is a Principal Scientist at Tessera Therapeutics since February 2022. Prior to this, Akinci held positions such as a Research Scientist at Harvard Medical School and Brigham and Women's Hospital, and Asst. Prof. Dr.-Group Leader at Akdeniz University Department of Biotechnology. With a background in Molecular Biology and Genetics, Akinci has led various research projects and initiatives in gene editing, CRISPR technology, and genome-wide screenings. Graduating with a PhD in Molecular Cellular Developmental Biology and Genetics, Akinci has a strong academic and research background.